Australia's largest stock trading and investment forum Australia's #1 stock forum

PER

0.00%

10.5¢ percheron therapeutics limited

And then of course there are the other inflammation diseases....

First 3346 Last

Share
Profile

Follow
dalts66

4,364 Posts.

2034

03/11/23

14:54

Post #: 70715071
Share

Originally posted by dalts66: ↑

As it is for a paediatric disease with no SOC and little survival rate, I too think they will get the FDA nod. Adverse events have been reduced so safety is ok.

Not meeting the endpoints might Sway some medical professionals from wanting to use it, but parents will be desperate and willing to give it a try.

All of this will be in play when ANP take their results to the FDA/EMA. Remembering to try that 1102 targets inflammation, so a different mode of treatment for the disease, and with data showing previous treatment by exxon skipping drugs doesn't stop it from working, ANP should have a pretty good shot at goal.

Those same parents will still be interested, even after using a gene therapy, as they want every chance for their child. Roll out into ambulant boys should not be too much of a hurdle.

We are really looking at nearly 100% of DMD patients here. If we can show enough evidence. Sarepta have shown how the FDA look at approving drugs. ANP should be feeling pretty confident.

Look at the market cap ! its crazy low.

Last dosing of the tox study imminent. ATL 1102 is hitting arms. 8 or so months until we start seeing data. We have waited this long, but now there is a tiny light starting to shone on the horizon.

Expand

And then of course there are the other inflammation diseases.

Platform drug potential. How good is that!

ANP Price at posting: 6.0¢ Sentiment: Buy Disclosure: Held
13 Upvote

0 Great analysis

Reply

Top Stories

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 186 more messages in this thread...

First 3346 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $94.66M

Open	High	Low	Value	Volume
10.5¢	10.5¢	9.8¢	$58.09K	574.8K

Buyers (Bids)

No.	Vol.	Price($)
1	38503	10.0¢

Sellers (Offers)

Price($)	Vol.	No.
10.5¢	194063	5

View Market Depth

No.	Vol.	Price($)
1	38503	0.100
2	110101	0.099
2	108491	0.098
1	30927	0.097
1	10004	0.096

Price($)	Vol.	No.
0.105	194063	5
0.110	254663	3
0.115	1334300	6
0.120	381142	9
0.125	110429	2

Last trade - 16.10pm 04/10/2024 (20 minute delay)

PER (ASX) Chart

And then of course there are the other inflammation diseases....

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

And then of course there are the other inflammation diseases....

Top Stories

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News